← Leaderboards
Larry M Karnitz
Mayo Clinic Coll Of Medicine, Rochester
$10,584,921
Attributed
$10,741,029
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $946.2K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,741,029 · 9
By mechanism
R01$7,319,902 · 4
T32$2,019,292 · 2
P50$921,171 · 1
R56$270,782 · 1
R29$209,882 · 1
Top collaborators
- Doo-Sup Choi1 shared
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseProteinsPathway InteractionsDna RepairBaseAffectDna DamageMolecularMutationCellsPhosphorylationRelapseInsightChemotherapyPhosphotransferasesCytotoxicityTumorCancer PatientCancer CellMalignant Neoplasm Of OvaryInhibitor/AntagonistPreventComplexPre-Doctoral
Grant awards (42)
Project 3: Repurposing Ceritinib for Ovarian Cancer Therapy$228,197
P50 · FY2025 · CA · contact PI
Project 3: Repurposing Ceritinib for Ovarian Cancer Therapy$219,183
P50 · FY2024 · CA · contact PI
Predoctoral Training Program in Molecular Pharmacology$312,217
T32 · FY2022 · GM · contact PI
Project 3: Repurposing Ceritinib for Ovarian Cancer Therapy$236,635
P50 · FY2022 · CA · contact PI
Project 3: Repurposing Ceritinib for Ovarian Cancer Therapy$237,156
P50 · FY2021 · CA · contact PI
CDK12 in Ovarian Cancer$383,982
R01 · FY2020 · CA · contact PI
Predoctoral Training Program in Molecular Pharmacology$192,822
T32 · FY2020 · GM · contact PI
CDK12 in Ovarian Cancer$372,464
R01 · FY2019 · CA · contact PI
Targeting Chk1 in Acute Myeloid Leukemia$352,801
R01 · FY2019 · CA · contact PI
Predoctoral Training Program in Molecular Pharmacology$190,645
T32 · FY2019 · GM · contact PI
CDK12 in Ovarian Cancer$393,922
R01 · FY2018 · CA · contact PI
Targeting Chk1 in Acute Myeloid Leukemia$363,713
R01 · FY2018 · CA · contact PI
Predoctoral Training Program in Molecular Pharmacology$188,520
T32 · FY2018 · GM · contact PI
CDK12 in Ovarian Cancer$393,220
R01 · FY2017 · CA · contact PI
Targeting Chk1 in Acute Myeloid Leukemia$363,713
R01 · FY2017 · CA · contact PI
Predoctoral Training Program in Molecular Pharmacology$186,446
T32 · FY2017 · GM · contact PI
CDK12 in Ovarian Cancer$383,982
R01 · FY2016 · CA · contact PI
Targeting Chk1 in Acute Myeloid Leukemia$363,713
R01 · FY2016 · CA · contact PI
Predoctoral Training Program in Molecular Pharmacology$184,424
T32 · FY2016 · GM · contact PI
Targeting Chk1 in Acute Myeloid Leukemia$379,149
R01 · FY2015 · CA · contact PI
Predoctoral Training Program in Molecular Pharmacology$133,854
T32 · FY2015 · GM · contact PI
Predoctoral Training Program in Molecular Pharmacology$159,496
T32 · FY2014 · GM · contact PI
Predoctoral Training Program in Molecular Pharmacology$157,578
T32 · FY2013 · GM · contact PI
Predoctoral Training Program in Molecular Pharmacology$157,578
T32 · FY2012 · GM · contact PI
Predoctoral Training Program in Molecular Pharmacology$155,712
T32 · FY2011 · GM · contact PI
Analysis of a DNA Damage-Inducible Checkpoint Complex$270,782
R56 · FY2009 · CA · contact PI
Therapeutic targeting of HSP90-dependent signaling$258,036
R01 · FY2008 · CA · contact PI
Analysis of a DNA Damage-Inducible Checkpoint Complex$251,743
R01 · FY2008 · CA · contact PI
Therapeutic targeting of HSP90-dependent signaling$258,036
R01 · FY2007 · CA · contact PI
Analysis of a DNA Damage-Inducible Checkpoint Complex$251,743
R01 · FY2007 · CA · contact PI
Therapeutic targeting of HSP90-dependent singnaling$265,742
R01 · FY2006 · CA · contact PI
Analysis of a DNA Damage-Inducible Checkpoint Complex$259,261
R01 · FY2006 · CA · contact PI
Therapeutic targeting of HSP90-dependent singnaling$302,375
R01 · FY2005 · CA
Analysis of a DNA Damage-Inducible Checkpoint Complex$265,500
R01 · FY2005 · CA
Therapeutic targeting of HSP90-dependent signaling$302,375
R01 · FY2004 · CA
Analysis of a DNA Damage-Inducible Checkpoint Complex$265,500
R01 · FY2004 · CA
ANALYSIS OF A DNA DAMAGE INDUCIBLE CHECKPOINT COMPLEX$222,233
R01 · FY2003 · CA
ANALYSIS OF A DNA DAMAGE INDUCIBLE CHECKPOINT COMPLEX$222,233
R01 · FY2002 · CA
ANALYSIS OF A DNA DAMAGE INDUCIBLE CHECKPOINT COMPLEX$222,233
R01 · FY2001 · CA
CYTOKINE INDUCED SIGNALING AND CELL PROLIFERATION$106,614
R29 · FY2001 · CA
ANALYSIS OF A DNA DAMAGE INDUCIBLE CHECKPOINT COMPLEX$222,233
R01 · FY2000 · CA
CYTOKINE INDUCED SIGNALING AND CELL PROLIFERATION$103,268
R29 · FY2000 · CA